Hello Simply Wallstreet I have some DD on a small cap company I want to share. Firstly I want you all to be aware of the risks associated with small caps.Read more
Catalysts About LENZ Therapeutics LENZ Therapeutics develops and commercializes innovative ophthalmic therapies, led by VIZZ, a novel eye drop for presbyopia. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About LENZ Therapeutics LENZ Therapeutics develops and commercializes ophthalmic therapies, including VIZZ, a pharmacologic eye drop for the treatment of presbyopia in adults. What are the underlying business or industry changes driving this perspective?Read more
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
